Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication
Public ClinicalTrials.gov record NCT00102050. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NM-702 in Subjects With Intermittent Claudication
Study identification
- NCT ID
- NCT00102050
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Nissan Chemical Industries
- Industry
- Enrollment
- 390 participants
Conditions and interventions
Interventions
- NM-702 (phosphodiesterase inhibitor) Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2003
- Primary completion
- Not listed
- Completion
- Mar 31, 2006
- Last update posted
- May 18, 2006
2003 – 2006
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator | Long Beach | California | 90822 | — |
| Investigator | Riverside | California | 92501 | — |
| Investigator | San Diego | California | 92121 | — |
| Investigator | San Francisco | California | 94121 | — |
| Investigator | Torrance | California | 90502 | — |
| Investigator | Clearwater | Florida | 33761 | — |
| Investigator | Coral Gables | Florida | 33134 | — |
| Investigator | Jacksonville | Florida | 32216 | — |
| Investigator | Springfield | Illinois | 62702 | — |
| Investigator | Shawnee Mission | Kansas | 66204 | — |
| Investigator | New Orleans | Louisiana | 70124 | — |
| Investigator | New York | New York | 10003 | — |
| Investigator | Durham | North Carolina | 27705 | — |
| Investigator | Toledo | Ohio | 43606 | — |
| Investigator | Warwick | Rhode Island | 02886 | — |
| Investigator | San Antonio | Texas | 43606 | — |
| Investigator | Tacoma | Washington | 98431 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00102050, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2006 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00102050 live on ClinicalTrials.gov.